AC Immune gets another Genentech milestone

AC Immune S.A. (Lausanne, Switzerland) received a CHF14 million ($14.4 million) milestone payment from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) triggered by dosing of the first patient in a Phase I study of a mAb against microtubule-associated protein tau (MAPT; tau; FTDP-17).

AC Immune and Genentech are co-developing the mAb under a 2012 deal to develop anti-tau antibodies for Alzheimer's disease and other neurodegenerative indications (see BioCentury Extra, June 18, 2012). ...